Literature DB >> 25185105

Combination of bevacizumab and chemotherapy for platinum-resistant recurrent ovarian cancer: some observations about the AURELIA trial.

Federica Tomao1, Silverio Tomao2, Pierluigi Benedetti Panici2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25185105     DOI： 10.1200/JCO.2014.57.6231

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.

Authors:  Monika Haemmerle; Justin Bottsford-Miller; Sunila Pradeep; Morgan L Taylor; Hyun-Jin Choi; Jean M Hansen; Heather J Dalton; Rebecca L Stone; Min Soon Cho; Alpa M Nick; Archana S Nagaraja; Tony Gutschner; Kshipra M Gharpure; Lingegowda S Mangala; Rajesha Rupaimoole; Hee Dong Han; Behrouz Zand; Guillermo N Armaiz-Pena; Sherry Y Wu; Chad V Pecot; Alan R Burns; Gabriel Lopez-Berestein; Vahid Afshar-Kharghan; Anil K Sood
Journal:  J Clin Invest       Date:  2016-04-11       Impact factor: 14.808

Review 2.  Bevacizumab in ovarian cancer: A critical review of phase III studies.

Authors:  Luigi Rossi; Monica Verrico; Eleonora Zaccarelli; Anselmo Papa; Maria Colonna; Martina Strudel; Patrizia Vici; Vincenzo Bianco; Federica Tomao
Journal:  Oncotarget       Date:  2017-02-14

3.  Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.

Authors:  Su Jin Lee; Seon Young Lee; Weon Sup Lee; Jin San Yoo; Jong-Mu Sun; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Myung-Ju Ahn; Ho Yeong Lim; Won Ki Kang; Young Suk Park
Journal:  Invest New Drugs       Date:  2017-04-08       Impact factor: 3.850

4.  Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.

Authors:  Dana M Roque; Eric R Siegel; Natalia Buza; Stefania Bellone; Dan-Arin Silasi; Gloria S Huang; Vaagn Andikyan; Mitchell Clark; Masoud Azodi; Peter E Schwartz; Gautam G Rao; Jocelyn C Reader; Pei Hui; Joan R Tymon-Rosario; Justin Harold; Dennis Mauricio; Burak Zeybek; Gulden Menderes; Gary Altwerger; Elena Ratner; Alessandro D Santin
Journal:  Br J Cancer       Date:  2022-02-11       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.